high alpha fetoproteinemia of liver Cirrhosis,
Conditions
Interventions
therapy group :Ershu Jiedu Decoction Granules
Control group:Ershu Jiedu Decoction Granules Placebo
Sponsors
Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients with confirmed cirrhosis are not limited to men and women; (2) Age 18-65 years old; (3) AFP = 40 µg/L; (4) Sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with cirrhosis have ALT>2 x ULN or TBIL>2 x ULN, and hepatic encephalopathy, upper gastrointestinal bleeding, and hepatorenal syndrome are not included; (2) Genital embryogenic tumors, active liver diseases and patients with metastatic liver cancer; (3) AFP = 300 µg / L, or imaging examination of patients with liver occupying lesions; (4) Patients with severe heart, lung, gallbladder, kidney, endocrine, hematopoietic and neurological diseases; (5) Persons with disabilities in the legal sense; (6) Pregnant or lactating women, as well as those who have been pregnant and may not have effective contraceptive measures; (7) Allergic constitution (allergic to two or more drugs, food, pollen), or allergic to known ingredients of this drug; (8) Patients who participated in other clinical trials within the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alpha-fetoprotein;Alpha-fetoprotein heterogene;liver function;Liver ultrasound; | — |
Countries
China
Contacts
Public ContactYang Cheng
Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed